{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:37:17Z","timestamp":1789763837106,"version":"4.0.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.tips.2023.04.005","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T08:10:31Z","timestamp":1685520631000},"page":"411-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Artificial intelligence-driven drug development against autoimmune diseases"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-9983","authenticated-orcid":false,"given":"Philippe","family":"Moingeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2023.04.005_bb0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.tips.2023.04.005_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.coi.2019.11.006","article-title":"Complexity and heterogeneity, the defining features of autoimmune disease","volume":"61","author":"Sanz","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.tips.2023.04.005_bb0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tips.2023.04.005_bb0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jobcr.2021.02.009","article-title":"Exploring the role of immunotherapeutic drugs in autoimmune diseases: a comprehensive review","volume":"11","author":"Patil","year":"2021","journal-title":"J. Oral Biol. Craniofac. Res."},{"key":"10.1016\/j.tips.2023.04.005_bb0030","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2023.04.005_bb0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.tins.2022.12.004","article-title":"The foundation and architecture of precision medicine in neurology and psychiatry","volume":"46","author":"Hampel","year":"2023","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.tips.2023.04.005_bb0040","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41590-021-01044-7","article-title":"Immune-mediated inflammation across disease boundaries: breaking down research silos","volume":"22","author":"Buckley","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/23808993.2020.1804867","article-title":"A wide perspective of targeted therapies for precision medicine in autoimmune diseases","volume":"5","author":"Miyagawa","year":"2020","journal-title":"Expert. Rev. Precis. Med. Drug Dev."},{"key":"10.1016\/j.tips.2023.04.005_bb0050","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/rheumatology\/keab448","article-title":"Precision medicine in autoimmune diseases: fact or fiction","volume":"60","author":"Toro-Dominguez","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.tips.2023.04.005_bb0055","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41591-022-01880-6","article-title":"The promise of precision medicine in rheumatology","volume":"28","author":"Guthridge","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2023.04.005_bb0060","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision medicine in systemic lupus erythematosus","volume":"19","author":"Fasano","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tips.2023.04.005_bb0065","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.3390\/ijms22147506","article-title":"The potential of omics technologies for the treatment of immune-mediated inflammatory diseases","volume":"22","author":"Anchang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2023.04.005_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.668045","article-title":"Multi-omics approaches in immunological research","volume":"12","author":"Chu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001358","article-title":"Deep immunophenotyping at the single-cell level identifies a combination of anti-lL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy","volume":"8","author":"Nagaoka","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tips.2023.04.005_bb0080","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12859-021-04268-4","article-title":"A comprehensive database for integrated analysis of omics data in autoimmune diseases","volume":"22","author":"Martorell-Marugan","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.tips.2023.04.005_bb0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.drudis.2021.09.006","article-title":"Artificial intelligence-enhanced drug design and development: towards a computational precision medicine","volume":"27","author":"Moingeon","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2023.04.005_bb0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41591-022-02160-z","article-title":"The next generation of evidence-based medicine","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2023.04.005_bb0095","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41746-020-0229-3","article-title":"A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases","volume":"3","author":"Stafford","year":"2020","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.tips.2023.04.005_bb0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrrheum.2017.220","article-title":"Moving towards a molecular taxonomy of autoimmune rheumatic diseases","volume":"14","author":"Barturen","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tips.2023.04.005_bb0105","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-021-23472-7","article-title":"A new molecular classification to drive precision treatment strategies in primary Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Soret","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2023.04.005_bb0110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/1744666X.2023.2172404","article-title":"Biomarkers for autoimmune diseases: current status and new perspectives","volume":"19","author":"Laigle","year":"2023","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/bmm-2017-0297","article-title":"Biomarkers for Sj\u00f6gren's syndrome","volume":"12","author":"Baldini","year":"2018","journal-title":"Biomark. Med"},{"key":"10.1016\/j.tips.2023.04.005_bb0120","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/annrheumdis-2017-212888","article-title":"Rheumatology 4.0: big data, wearables and diagnosis by computer","volume":"77","author":"Burmester","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2023.04.005_bb0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/23808993.2021.1924055","article-title":"Value of digital biomarkers in precision medicine: implications in cancer, autoimmune diseases, and COVID-19","volume":"6","author":"Capobianco","year":"2021","journal-title":"Expert. Rev. Precis. Med. Drug Dev."},{"key":"10.1016\/j.tips.2023.04.005_bb0130","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/art.41610","article-title":"Integrative analysis reveals a molecular stratification of systemic autoimmune diseases","volume":"73","author":"Barturen","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2023.04.005_bb0135","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1038\/s41467-021-24584-w","article-title":"Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data","volume":"12","author":"Altman","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2023.04.005_bb0140","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/art.41708","article-title":"Two shared immune cell signatures stratify patients with Sj\u00f6gren's syndrome and systemic lupus erythematosus with potential therapeutic implications","volume":"73","author":"Martin-Gutierrez","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2023.04.005_bb0145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s13075-014-0489-x","article-title":"Shared signatures between rheumatoid arthritis, systemic lupus erythematosus and Sj\u00f6gren's syndrome uncovered through gene expression meta-analysis","volume":"16","author":"Toro-Dominguez","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tips.2023.04.005_bb0150","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fimmu.2020.00380","article-title":"Development of a bioinformatics framework for identification and validation of genomic biomarkers and key immunopathology processes and controllers in infectious and non-infectious severe inflammatory response syndrome","volume":"11","author":"Tong","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0155","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.drudis.2018.05.028","article-title":"Understanding drug targets: no such thing as bad news","volume":"23","author":"Roberts","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2023.04.005_bb0160","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.drudis.2021.06.010","article-title":"IFN-\u03b1: a key therapeutic target for multiple autoimmune rheumatic diseases","volume":"26","author":"De Ceuninck","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2023.04.005_bb0165","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/art.42265","article-title":"Variability in primary Sj\u00f6gren's syndrome is driven by interferon alpha, and genetically associated with the class II HLA DQ locus","volume":"12","author":"Trutschel","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2023.04.005_bb0170","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/1744666X.2022.2012452","article-title":"Model-based computational precision medicine to develop combination therapies for autoimmune diseases","volume":"18","author":"Desvaux","year":"2022","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0175","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.tips.2023.04.005_bb0180","doi-asserted-by":"crossref","first-page":"bbac332","DOI":"10.1093\/bib\/bbac332","article-title":"Scoring personalized molecular portraits identify systemic lupus erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression","volume":"23","author":"Toro-Dominguez","year":"2022","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.tips.2023.04.005_bb0185","doi-asserted-by":"crossref","first-page":"E85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"2","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.tips.2023.04.005_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254374","article-title":"Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19","volume":"16","author":"Desvaux","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2023.04.005_bb0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41584-019-0337-0","article-title":"Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases","volume":"16","author":"Kingsmore","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tips.2023.04.005_bb0200","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.tips.2023.04.005_bb0205","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","article-title":"Applications of machine learning in drug discovery and development","volume":"18","author":"Vamathevan","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2023.04.005_bb0210","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/s41587-022-01307-0","article-title":"Prediction of protein\u2013ligand binding affinity from sequencing data with interpretable machine learning","volume":"40","author":"Rube","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2023.04.005_bb0215","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/antib9020012","article-title":"Review of deep learning methods for antibodies","volume":"9","author":"Graves","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.tips.2023.04.005_bb0220","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41551-021-00699-9","article-title":"Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning","volume":"5","author":"Mason","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.tips.2023.04.005_bb0225","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.drudis.2021.09.008","article-title":"Agonist antibody discovery: experimental, computational, and rational engineering approaches","volume":"27","author":"Schardt","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2023.04.005_bb0230","doi-asserted-by":"crossref","first-page":"E260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.tips.2023.04.005_bb0235","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1186\/s13063-022-06874-w","article-title":"Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial","volume":"23","author":"van Schaik","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.tips.2023.04.005_bb0240","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/13816128113199990470","article-title":"Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles","volume":"20","author":"Tang","year":"2014","journal-title":"Curr. Pharm. Design."},{"key":"10.1016\/j.tips.2023.04.005_bb0245","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.csbj.2022.05.055","article-title":"Systematic review of computational methods for drug combination prediction","volume":"20","author":"Kong","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.tips.2023.04.005_bb0250","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and external controls in clinical trials \u2013 a primer for researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.tips.2023.04.005_bb0255","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1093\/eurheartj\/ehaa159","article-title":"The digital twin to enable the vision of precision cardiology","volume":"41","author":"Corral-Acero","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.tips.2023.04.005_bb0260","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/jpm11080745","article-title":"Digital twins: from personalised medicine to precision public health","volume":"11","author":"Kamel Boulos","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.tips.2023.04.005_bb0265","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41746-022-00610-z","article-title":"Building digital twins of the human immune system: toward a roadmap","volume":"5","author":"Laubenbacher","year":"2022","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.tips.2023.04.005_bb0270","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.09.025","article-title":"Genetic ancestry and natural selection drive population differences in immune responses to pathogens","volume":"167","author":"Nedelec","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.tips.2023.04.005_bb0275","article-title":"The role of the gut microbiome in systemic inflammatory disease","volume":"360","author":"Clemente","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.tips.2023.04.005_bb0280","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2014.12.004","article-title":"The Milieu Int\u00e9rieur study, an integrative approach for study of human immunological variance","volume":"157","author":"Thomas","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0285","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nri.2016.125","article-title":"Human immune system variation","volume":"17","author":"Brodin","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.669811","article-title":"Digital twins for multiple sclerosis","volume":"12","author":"Voigt","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10928-021-09790-9","article-title":"Recent applications of quantitative systems pharmacology and machine learning models across diseases","volume":"49","author":"Aghamiri","year":"2022","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.tips.2023.04.005_bb0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10928-022-09805-z","article-title":"Two heads are better than one: current landscape of integrating QSP and machine learning","volume":"49","author":"Zhang","year":"2022","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.tips.2023.04.005_bb0305","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/17460441.2022.2095368","article-title":"Industrializing Al-powered drug discovery: lessons learned from the Patrimony computing platform","volume":"17","author":"Guedj","year":"2022","journal-title":"Expert. Opin. Drug Discov."},{"key":"10.1016\/j.tips.2023.04.005_bb0310","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/d41573-022-00025-1","article-title":"Al in small-molecule drug discovery: a coming wave?","volume":"21","author":"Jayatunga","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2023.04.005_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cotox.2018.03.004","article-title":"The adverse outcome pathway: a multifaceted framework supporting 21st century toxicology","volume":"9","author":"Ankley","year":"2018","journal-title":"Curr. Opin. Toxicol."},{"key":"10.1016\/j.tips.2023.04.005_bb0320","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drudis.2018.07.001","article-title":"How soon will digital endpoints become a cornerstone for future drug development?","volume":"24","author":"Boehme","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2023.04.005_bb0325","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/sdata.2016.18","article-title":"The FAIR Guiding Principles for scientific data management and stewardship","volume":"3","author":"Wilkinson","year":"2016","journal-title":"Sci. Data"},{"key":"10.1016\/j.tips.2023.04.005_bb0330","series-title":"Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions","author":"US Food and Drug Administration","year":"2021"},{"key":"10.1016\/j.tips.2023.04.005_bb0335","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/art.40653","article-title":"Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression","volume":"70","author":"Toro-Dominguez","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2023.04.005_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100291","article-title":"Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study","volume":"20","author":"Guthridge","year":"2020","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.tips.2023.04.005_bb0345","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122312","article-title":"Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus","volume":"5","author":"Haynes","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2023.04.005_bb0350","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/rheumatology\/keaa379","article-title":"Classifying and diagnosing systemic lupus erythematosus in the 21st century","volume":"59","author":"Aringer","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.tips.2023.04.005_bb0355","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41590-020-0743-0","article-title":"Mapping systemic lupus erythematosus heterogeneity at the single-cell level","volume":"21","author":"Nehar-Belaid","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0360","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","article-title":"The immune cell landscape in kidneys of patients with lupus nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0365","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.41253","article-title":"Early disease and low baseline damage as predictors of response to nelimumab in patients with systemic lupus erythematosus real life setting","volume":"72","author":"Gato","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2023.04.005_bb0370","first-page":"4462","article-title":"Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus","volume":"10","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2023.04.005_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606268","article-title":"Transcriptomic and network analysis of minor salivary glands of patients with primary Sj\u00f6gren's syndrome","volume":"11","author":"Oyelakin","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.681941","article-title":"The transcriptome of paired major and minor salivary gland tissue in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Verstappen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0385","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3389\/fimmu.2019.01459","article-title":"A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis","volume":"10","author":"Aterido","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0390","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/rheumatology\/keab521","article-title":"Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis","volume":"61","author":"Yossuf","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.tips.2023.04.005_bb0395","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fmed.2018.00364","article-title":"IL-17 in rheumatoid arthritis and precision medicine: from synovitis expression to circulating bioactive levels","volume":"5","author":"Robert","year":"2019","journal-title":"Front. Med."},{"key":"10.1016\/j.tips.2023.04.005_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790122","article-title":"Molecular and cellular heterogeneity in rheumatoid arthritis: mechanisms and clinical implications","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0405","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3389\/fgene.2020.00816","article-title":"Identification and validation of key genes associated with systemic sclerosis-related pulmonary hypertension","volume":"11","author":"Zheng","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.tips.2023.04.005_bb0410","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/annrheumdis-2020-217116","article-title":"Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients","volume":"79","author":"Beretta","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2023.04.005_bb0415","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.cell.2022.03.011","article-title":"LGRS5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma","volume":"185","author":"Gur","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.tips.2023.04.005_bb0420","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.3390\/jcm11154631","article-title":"New era in systemic sclerosis treatment: recently approved therapeutics","volume":"11","author":"Ebata","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tips.2023.04.005_bb0425","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/cells8060535","article-title":"Molecular profiling of inflammatory bowel disease: is it ready for use in clinical decision-making?","volume":"8","author":"Lee","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.tips.2023.04.005_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.653924","article-title":"Precision medicine in inflammatory bowel diseases","volume":"12","author":"Marafini","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2023.04.005_bb0435","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3389\/fimmu.2018.01693","article-title":"Immunophenotype and transcriptome profile of patients with multiple sclerosis treated with fingolimod: setting up a model for prediction of response in a 2-year translational study","volume":"9","author":"Moreno-Torres","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.005_bb0440","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/all.15119","article-title":"Identification of chronic urticaria subtypes using machine learning algorithms","volume":"77","author":"Turk","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.tips.2023.04.005_bb0445","first-page":"803","article-title":"Unveiling chronic spontaneous urticaria pathophysiology through 2 systems biology","volume":"12","author":"Segu-Verges","year":"2023","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614723000883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614723000883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:14:46Z","timestamp":1759050886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614723000883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":89,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0165614723000883"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2023.04.005","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial intelligence-driven drug development against autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2023.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}